Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
DexCom, Inc. (NASDAQ: DXCM) has appointed Kyle Malady to its Board of Directors, effective immediately. Malady currently serves as executive vice president and chief technology officer at Verizon, overseeing global network operations and IT functions. With over 30 years of experience in mobile communications technology, Malady's extensive background is expected to enhance DexCom's leadership in continuous glucose monitoring and data analytics. His appointment aims to bolster DexCom’s efforts to empower diabetes management.
DexCom, Inc. (NASDAQ:DXCM) is set to release its third quarter 2020 financial results on October 27, 2020, after market close. A conference call will follow at 4:30 p.m. Eastern Time, where management will discuss the company's performance. Interested parties can access the call by dialing (800) 447-0521 (US/Canada) or (847) 413-3238 (International) with confirmation number '49260065'. DexCom is a leader in continuous glucose monitoring systems, dedicated to improving diabetes management for users, caregivers, and healthcare providers.